Identifying Rare Genetic Variation In Obsessive-Compulsive Disorder by Abdallah, Sarah
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Yale Medicine Thesis Digital Library School of Medicine 
January 2020 
Identifying Rare Genetic Variation In Obsessive-Compulsive 
Disorder 
Sarah Abdallah 
Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl 
Recommended Citation 
Abdallah, Sarah, "Identifying Rare Genetic Variation In Obsessive-Compulsive Disorder" (2020). Yale 
Medicine Thesis Digital Library. 3876. 
https://elischolar.library.yale.edu/ymtdl/3876 
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A 
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital 
Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more 











A Thesis Submitted to the Yale University School of Medicine 
in Partial Fulfillment of the Requirements for the 










IDENTIFYING RARE GENETIC VARIATION IN OBSESSIVE-COMPULSIVE 
DISORDER 
Sarah B. Abdallah, Carolina Cappi, Emily Olfson, and Thomas V. Fernandez. Child 
Study Center, Yale University School of Medicine, New Haven, CT 
 
Obsessive-compulsive disorder (OCD) is a neuropsychiatric developmental 
disorder with known heritability (estimates ranging from 27%-80%) but poorly 
understood etiology. Current treatments are not fully effective in addressing chronic 
functional impairments and distress caused by the disorder, providing an impetus to study 
the genetic basis of OCD in the hopes of identifying new therapeutic targets. We 
previously demonstrated a significant contribution to OCD risk from likely damaging de 
novo germline DNA sequence variants, which arise spontaneously in the parental germ 
cells or zygote instead of being inherited from a parent, and we successfully used these 
identified variants to implicate new OCD risk genes. Recent studies have demonstrated a 
role for DNA copy-number variants (CNVs) in other neuropsychiatric disorders, but 
CNV studies in OCD have been limited. Additionally, studies of autism spectrum 
disorder and intellectual disability suggest a risk contribution from post-zygotic variants 
(PZVs) arising de novo in multicellular stages of embryogenesis, suggesting these mosaic 
variants can be used to study other neuropsychiatric disorders. In the studies presented 
here, we aim to characterize the contribution of PZVs and rare CNVs to OCD risk. 
We examined whole-exome sequencing (WES) data from peripheral blood of 184 
OCD trio families (unaffected parents and child with OCD) and 777 control trios that 
passed quality control measures. We used the bioinformatics tool MosaicHunter to 
identify low–allele frequency, potentially mosaic single-nucleotide variants (SNVs) in 
probands (OCD cases) and in control children. We then applied the XHMM tool to 101 
of the OCD trio families and to the 777 control trio families, all generated with the same 
capture library and platform, to identify CNVs. 
The rate of all single-nucleotide PZVs per base pair was not significantly different 
between OCD probands (4.90 x 10-9) and controls (4.93 x 10-9), rate ratio = 0.994, p = 1. 
The rate of likely-damaging PZVs (those altering a stop codon or splice site) also is not 
significantly different in OCD probands (1.45 x 10-9) than in controls (1.09 x 10-9), rate 
ratio = 1.33, p = 0.653. 
When examining CNVs, the proportion of children with at least one rare 
duplication or deletion is not significantly different between OCD cases (0.869) and 
controls (0.796), chi-square = 2.97, p = 0.0846. However, when considering deletions 
separately from duplications, the proportion of children with at least one rare deletion is 
higher in OCD trios (0.606) than in controls (0.448), chi-square = 8.86, p = 0.00292. 
Although we did not detect a higher burden of PZVs in blood in individuals with 
OCD, further studies may benefit from examining a larger sample of families or from 
looking for PZVs in other tissues. The higher rate of de novo deletions in cases vs. 
controls suggests they may contribute to OCD risk, but further work is needed to 
experimentally validate the detected CNVs. We hope to eventually use these CNVs to 
identify OCD risk genes that could provide jumping-off points for future studies of 
molecular disease mechanisms. 
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Features of Obsessive-Compulsive Disorder 
Obsessive-compulsive disorder (OCD) is a developmental neuropsychiatric 
disorder with estimated prevalence of 1-3% worldwide. It is characterized by disabling 
obsessions (intrusive, unwanted thoughts, sensations, or urges) and compulsions 
(ritualized, repetitive behaviors that are difficult to control) (1). These symptoms can 
cause distress, significantly compromise the affected individual’s social and occupational 
functioning, and lead to increased risk of mortality, such that the World Health 
Organization has named OCD among the ten most disabling medical conditions 
worldwide (2). Although serotonergic antidepressants have been used in the treatment of 
OCD for several decades, these pharmacologic treatments are not completely effective, 
producing 30-50% reduction of symptoms in 60-80% of patients, and untreated OCD 
tends to persist and become chronic (2, 3). The main barrier to developing more effective 
therapeutic options for OCD is a poor understanding of its underlying etiology. For this 
reason, there is great incentive to study the molecular basis of the disorder in the hopes of 
identifying new therapeutic targets. 
Like many neuropsychiatric disorders, OCD has high clinical heterogeneity, with 
a wide range of possible symptoms and severity, such that different patients with the 
disorder may have little to no phenotypic overlap. Efforts to better understand this 
heterogeneity have used factor-analytic and clustering approaches to identify symptom 
dimensions or subtypes in OCD (4-6). However, large-scale genetic studies generally 
group together phenotypically divergent patients, potentially diluting genetic signals that 
may be specific to a subgroup of patients. Further complicating efforts, OCD often is 
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comorbid with other neuropsychiatric disorders, namely tic disorders, creating the 
potential for confounding signals in genetic studies (5, 6). 
 OCD is thought to arise from a combination of genetic and environmental factors. 
Twin and family studies have demonstrated substantial heritability of OCD, with 
estimates around 27-47% for adult-onset cases and 40-80% for early-onset (childhood) 
OCD (1, 7-15). Despite evidence for a significant genetic contribution to OCD 
pathogenesis, risk gene discovery efforts have had little success so far, and the underlying 
genetic basis of the disorder remains poorly understood. It is challenging to identify these 
responsible genetic variants and genes because OCD is highly polygenic, meaning many 
genes contribute to the disorder, and the combination of genetic factors contributing OCD 
risk differs between patients (15-17). Current prevailing wisdom suggests a combination 
of small-effect common variants and large-effect rare variants, either inherited from 
parents or arising spontaneously, in hundreds of genes and within the intergenic space 
contribute to OCD pathogenesis (16, 17). This complexity requires geneticists to draw 
from different types of genetic information and methods of analysis to statistically 
implicate risk genes. 
  
Approaches to Studying OCD Genetics 
Investigations into the genetic basis of OCD have taken several approaches to 
uncovering the relevant genes, types of variation, and biological pathways involved in the 
disorder (7, 15). The following section examines the relative success and findings of 





 To date, few genome-wide association studies (GWAS) exploring the contribution 
of common genetic variation to OCD have been conducted. Stewart et al. (18) performed 
a meta-analysis of 1,465 cases, 5,557 ancestry-matched controls, and 400 parent-child 
trios, while Mattheisen et al. (19) examined 1,406 individuals with OCD from 1,065 
families. In the individual studies and a meta-analysis of both by the International OCD 
Foundation (20), no loci reached genome-wide statistical significance (p < 5 x 10-8) in the 
final analyses. While GWAS overall have been unsuccessful in identifying reproducible 
genetic associations with OCD, common variants of small effect sizes are thought to 
contribute partially to OCD heritability, and the lack of success with GWAS so far may 
be due to insufficient sample sizes (16, 18, 19, 21). One would expect that a relatively 
large proportion of loci approaching genome-wide significance would cross the 
significance threshold in future GWAS with larger sample sizes. By this supposition, 
overall trends or pathway enrichment among genes in these loci may still point to 
relevant biology. 
In contrast with the hypothesis-free nature of GWAS, candidate gene association 
studies focus on single nucleotide polymorphisms (SNPs) within a preselected gene 
hypothesized to be biologically relevant to a disease. While over 100 of these studies 
have been conducted in OCD, few consistent findings have been reported (1, 8). Due to 
issues of publication bias and failure to account for environmental and genetic 
background of participants, among other factors, candidate gene studies are prone to false 
positive results that largely have not been replicated (22-27). Further, many lack the 
sample size needed to detect the small effects expected for complex disorders like OCD 
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(26, 28). A meta-analysis of 230 polymorphisms from 113 candidate association studies 
found a statistically significant association between OCD and alleles of two serotonergic 
genes (5-HTTLPR and HTR2A) among all patients; among males only, it found a 
significant association between OCD and COMT and MAOA alleles (28). Since the 
publication of this meta-analysis, replicability of these results has been mixed, with 
successful replication of the association with OCD for the common LA allele of 5-
HTTLPR but not for gene polymorphisms of HTR2A, COMT, and MAOA (29-31). 
Unfortunately, because the genes or loci of interest are selected based on presupposition, 
candidate gene studies are less useful in uncovering novel biology underlying disease 
pathogenesis.  
 
Rare Variation in Psychiatric Disease 
While the aforementioned association studies attempt to pinpoint common 
variation contributing to disease risk, other study designs leverage information about rare 
variation to infer biology underlying disease. Investigation of rare variation in autism 
spectrum disorder (ASD) has successfully associated several genes with ASD risk and 
implicated specific brain regions and developmental timepoints in its pathogenesis (32), 
suggesting these approaches hold promise. 
 
Linkage Studies of Rare Inherited Variants 
Because a child inherits about four to five million rare variants from their parents, 
there is low statistical power to detect which of these variants fall in disease risk genes 
and are contributing to disease risk in a patient cohort. Further, because inherited variants 
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are subject to natural selection pressure while passing through generations, those that 
persist are unlikely to have high damaging capacity (33). Thus, the utility of these 
variants in implicating disease risk genes is limited to cases of families with multiple 
affected individuals carrying very rare, large-effect inherited variants. In these families, 
linkage studies can identify putative causal variants that associate with affected status 
within the family (34). While several genome-wide linkage studies have been conducted 
in OCD, few loci have reached genome-wide statistical significance and none have been 
replicated (35-39). 
 
De Novo Variation 
 De novo variants arise spontaneously in the child due to DNA replication errors 
and are not inherited from parents. In contrast to inherited variants, de novo single-
nucleotide variants arising in the germline (egg or sperm) or zygote are infrequent, 
occurring on average 44-82 times throughout a person’s genome and only once or twice 
in the coding regions, or exome (33). This rarity makes them much more useful for 
detecting disease risk genes across cohorts. Genetic studies of other psychiatric disorders 
have successfully harnessed de novo variants as a powerful means of identifying disease 
risk genes (40-43). Recently, our group has applied this approach to OCD (see 
preliminary studies) with success (44). 
 
Post-Zygotic Variants 
 Post-zygotic variants (PZVs), de novo variants arising soon after conception 
rather than in the parental germ cells, produce a mosaic child with the variant in only a 
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fraction of cells throughout the body. Figure 1 depicts the different developmental 
timepoints at which germline de novo variants and PZVs arise. In contrast to oncogenic 
somatic mutations that can accumulate over an individual’s lifetime, PZVs occur in early 
embryogenesis and theoretically should appear in multiple cell and tissue types 
descended from the original embryonic cell. With high depths of coverage, next-
generation sequencing allows for detection of potential mosaic variants based on the 
observed mutant allele fraction, or the fraction of DNA segments with the variant allele at 
a genomic position. Germline de novo variants theoretically should have a mutant allele 
fraction of 50%, so any variants below a certain cutoff (e.g. 30%) are discarded as likely 
technical artifacts (45). However, PZVs should have a mutant allele fraction far below 
50% and likely produce true signal buried among these discarded variants. 
 
Figure 1. Consequences of spontaneous variants in offspring. (A) A germline de novo 
variant arises in one parental germ cell and propagates through all cells of the child’s 
germline zygote embryo 
mosaic 






body, producing a child who is heterozygous for the variant. (B) After the zygote has 
split into a multicellular embryo, a PZV arises in one of the cells and propagates through 
the cell’s descendants, producing a child who is mosaic for the variant. 
 
PZVs have been of recent interest in the study of several neuropsychiatric 
disorders but are poorly understood within the context of these disorders. Recent studies 
looking at previously identified de novo variants in ASD (46-49) and intellectual 
disability (50) have shown that 5.8% and 6.5%, respectively, were in fact post-zygotic 
rather than germline mutations. Several studies found that PZVs were enriched (more 
frequent) in ASD probands (clinically affected individuals with unaffected parents and 
siblings) compared to their unaffected siblings, and by one estimate the detected PZVs 
contributed to 5.1% of ASD diagnoses, suggesting a role for somatic mosaicism in ASD 
(46-49). These findings suggest that mosaic variation may provide a fruitful avenue to 
examine the genetic underpinnings of neuropsychiatric disorders and may contribute 
clinically meaningful genetic risk that previously was overlooked. 
  
Structural (Copy Number) Variation 
Examination of chromosomal structural variation, defined as variation in DNA 
segments over one kilobase (kb) in length, has suggested a role in OCD pathogenesis. 
Early cytogenetic and locus-specific studies of OCD cases identified inversions or 
translocations of large DNA segments that converged on overlapping chromosomal 
locations (15, 51). DNA microarrays, which provide better genome-wide resolution than 
older cytogenetic techniques such as karyotyping, have improved detection of copy-
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number variants (CNVs; deletions or duplications of DNA sequences over one kb in 
length) in recent years. Three microarray studies of CNVs in OCD found no overall 
increased rate compared to controls. However, one study found that OCD cases harbored 
a significantly higher rate of large deletions overlapping regions implicated in other 
neurodevelopmental disorders, and the other two found a significantly higher rate of rare 
CNVs affecting genes related to neurological function (11, 51, 52). 
While microarrays have improved resolution compared to older techniques like 
karyotyping and fluorescence in situ hybridization (FISH), they still are best at detecting 
larger CNVs with a lower limit of about 30 kb in size. In contrast, high-throughput 
sequencing approaches like WES can be used to more accurately detect small- to 
medium-sized CNVs, which are more frequent in number compared to large CNVs (33, 
53). Rare exonic deletions of 1-30 kb size have been estimated to contribute to disease 
risk in up to 7% of ASD cases. Further, unlike large CNVs that typically contain multiple 
genes, small exonic CNVs typically affected just one gene, making them useful for risk 
gene discovery and pathway analysis (53). It is possible rare, smaller CNVs impart a 
previously undetected contribution to OCD pathogenesis as well and can provide new 
insights into underlying biology. 
 
Preliminary Studies 
Our group recently published the first analysis of rare inherited and germline de 
novo single-nucleotide variants (SNVs) and insertion-deletion variants (indels) in patients 
with OCD. The cohort collected for this study exclusively contained simplex probands 
(affected individuals with no known affected first-degree relatives) to increase the 
likelihood of detecting de novo variants. After quality control, analyses were conducted 
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on whole-exome sequencing (WES) from peripheral blood in 184 OCD parent-proband 
trios (families comprising two unaffected parents and one affected child) and in 777 
control trios (unaffected parents and child). Among this cohort, likely-damaging germline 
de novo variants were enriched in OCD probands compared to controls. These damaging 
variants include likely gene-disrupting variants (LGD; nonsense, frameshift, or splice site 
mutations) and missense mutations predicted to be damaging by the software PolyPhen2 
(Mis-D). The study also estimated that de novo variants found within 335 genes 
contributed to risk in 22% of cases (44). These findings suggest a significant contribution 
of de novo SNVs and indels to OCD risk. Identification of these variants implicated two 
new OCD risk genes, CHD8 and SCUBE1, based on gene-level recurrence, i.e. the 
presence of at least two damaging (LGD or Mis-D) de novo variants in the same gene in 




Figure 2. Germline de novo SNVs and indels in OCD probands vs. controls. Compared 
to control children, OCD probands have significantly higher rates of Mis-D, LGD, and 
total damaging germline de novo variants compared to controls. In contrast, synonymous 
variants, which do not affect a gene’s protein product, are not expected to contribute to 
OCD pathogenesis and are not more frequent in cases compared to controls. Figure 
modified from Cappi et al. (44). 
 
With an increased sample size of trios, we expect to identify additional risk genes, 
particularly among the set of genes with one identified damaging variant to date. These 
studies are underway. In the meantime, we can extend the value of our current sample by 
















































account for some missing information about OCD’s genetic basis and can provide 
additional information to use in risk gene analyses. 
 
Statement of Purpose and Specific Aims 
We intend to build on our previous work using rare genetic variation detected in 
WES of OCD trios to gain insights into the underlying biology of OCD. The overarching 
purpose is to implement tools to identify two additional types of genetic variation from 
our WES data, characterize the contribution of that variation to OCD risk, and use those 
variants in statistical analyses to identify new potential OCD risk genes. These 
approaches have not yet been described in the literature and could provide promising new 
avenues to elucidate the genetic basis of OCD. This project will serve to fill a large 
knowledge gap by providing insight into OCD genetics, paving the way for further 
molecular and mechanistic studies of the disorder. 
 
Aim 1: Characterize the Contribution of PZVs to OCD 
The potential role of mosaic variation has not yet been described in the OCD 
literature but could add to our understanding of the genetic etiology of OCD. We aim to 
implement and optimize a computational approach to detect PZVs from WES data and to 
characterize the burden of PZVs in OCD cases versus control probands. With our depth 
of sequencing coverage in cases (76 reads per position on average) we can expect to 
detect over 95% of SMVs with a mutant allele fraction of at least 20% and over 90% of 
SMVs with a mutant allele fraction of at least 10% (54). Like our finding for damaging 
germline de novo variants, we hypothesize that PZVs predicted to be damaging will have 
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an increased burden (occur at a greater frequency) in OCD probands compared to 
controls, suggesting a role for PZVs in OCD pathogenesis. 
 
Aim 2: Characterize the Contribution of CNVs to OCD 
 The few studies that have explored the role of CNVs in OCD have used 
microarray data, which has limited resolution compared to sequencing. We anticipate we 
will be able to detect more CNVs from our WES data for OCD families. While WES 
covers only the exome (the coding region of the genome) and cannot be used to detect 
portions of CNVs in noncoding regions, we would expect the majority of the most 
clinically significant CNVs to occur in coding regions so that they will severely impact 
gene dosage. We aim to develop and optimize a computational approach to detect rare 
inherited and de novo CNVs from our WES of OCD and control trios. Based on previous 
findings in the literature, we expect to find an increased burden of deletions in probands 
compared to controls. 
 
Aim 3: Identify New OCD Risk Genes and Biological Pathways 
We will use the variants detected in the first two aims to identify putative OCD 
risk genes. Genes containing multiple germline or mosaic de novo variants or overlapping 
novel de novo CNVs will be deemed to possibly contribute OCD risk. We will construct 
networks of genes co-expressed across space and time in brain development and look for 
networks enriched for OCD risk genes, which could point to specific brain regions and 
developmental timepoints underlying OCD pathogenesis. Presuming correlated 
expression levels across space and time suggest similar function or regulation for a set of 
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genes, we can associate other genes within these networks with OCD as well (32). We 
also will use gene ontology and pathway analysis tools to associate specific biological 
pathways with the set of risk genes. 
 
MATERIALS AND METHODS 
Data collection and processing 
Participant recruitment, sample collection, and whole-exome sequencing (WES) 
were performed as described in Cappi et al., 2019 (44). In brief, we generated WES data 
from peripheral blood DNA of 222 parent-child OCD trios collected from sites in 
Toronto, Canada; São Paulo, Brazil; and New Haven, USA; and from a separate Tourette 
International Collaborative Genetics study that included patients with both OCD and 
chronic tics (55, 56). All samples were sequenced at the Yale Center for Genome 
Analysis (YCGA) using the NimbleGen SeqCap EZExomeV2 (109 trios) or MedExome 
(113 trios) capture libraries (Roche NimbleGen, Madison, WI) and the Illumina HiSeq 
2000 platform (74-bp paired-end reads) (Illumina, San Diego, CA). These data were 
compared to WES from peripheral blood DNA in 855 control trios without OCD from the 
Simons Simplex Collection (57), sequenced at YCGA using the NimbleGen SeqCap 
EZExomeV2 and the Illumina HiSeq 2000 platform. These WES data were aligned using 
our lab’s well-validated analysis pipeline following the latest Genome Analysis Toolkit 
(GATK) Best Practices guidelines (58). From this sample set, we retained 184 OCD trios 
(117 male probands; 67 female) and 777 control trios (356 male children; 421 female) 
that passed strict quality control measures, including removal of outlier trios based on 
principal component analysis of sequencing quality metrics (44). 
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Following sample collection and data processing, I performed all elements of the 
work described below, including the development and implementation of variant (PZV 




In-house computational pipelines built from pre-existing tools were developed to 





Figure 3. Variant calling pipelines for samples from the OCD Sequencing Consortium 
(44) and Simons Simplex Collection (57). (A) 184 OCD trios and 777 control trios 
passed quality control (QC) metrics for exome sequencing and all were included in the 
PZV analysis. PZVs were detected with MosaicHunter (59) and subsequently filtered to 
remove likely false positive variant calls. (B) 101 OCD trios and 777 control trios 
sequenced with the same capture library were used to call CNVs, which were detected 
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with XHMM and classified as transmitted (inherited) or de novo in the children using 
PLINK and PLINK/Seq tools (60, 61). 
 
PZV Calling with MosaicHunter 
 We called putative PZVs from our aligned and indexed WES for 184 OCD trios 
and 777 control trios passing QC with MosaicHunter, a Bayesian-based genotyping tool 
(Figure 3A). MosaicHunter was developed to call single-nucleotide mosaic variants in 
non-cancer contexts, i.e. when a known normal control from the same individual is not 
available to compared to the tissue of interest (59). We used the trio mode of the tool, 
which incorporates WES from the parents into the calling algorithm, and the exome 
mode, which employs a beta-binomial model that accounts for capture bias and over-
dispersion in WES to better fit the data. We applied these settings to our WES to identify 
low–allele frequency, potentially mosaic SNVs in probands and in control children. 
MosaicHunter was set to discard variants with a frequency of more than 0.05 in the 
Single Nucleotide Polymorphism Database (62), variants with ≥10 sequencing reads in 
the parents and ≥25 reads in the child, and variants falling in regions with indels or CNVs 
in the child. All other parameters were left as their default settings, and reference genome 
b37d5 was used (b37 human reference genome with decoy sequences). For each trio, 
MosaicHunter generated an output file containing all calls found to violate Mendelian 
inheritance, i.e. both de novo germline variants and PZVs. We discarded the output for 
one outlier OCD trio with an excess of variants. 
In addition to the filtering steps built into MosaicHunter, we applied inclusion 
criteria to the output data to reduce the number of false positive PZVs in our final dataset. 
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These criteria include: ≥0.7 posterior probability of being mosaic in the child, ≥1 child 
likelihood ratio of mosaic vs. heterozygous, ≥0.5 posterior probability each parent does 
not carry the alternate allele (reference homozygous genotype), no more than two reads 
with the alternate allele in either parent, no duplicates of the variant across families, and 
≤0.001 (<0.1%) frequency in non-Finnish European populations according to the Exome 
Aggregation Consortium (ExAC) database (63). We removed all G>T variants with fewer 
than 8 T alleles, as these are highly likely to be false positive calls caused by oxidative 
damage to samples after collection (64). 
 
CNV Calling with XHMM 
We called putative CNVs from the same WES data, using 101 of the OCD trios 
that were sequenced with the same capture library (Nimblegen EZ Exome V2) as the 777 
control trios (Figure 3B). Sequencing read depths were calculated using GATK’s 
DepthOfCoverage tool. Calls were generated using eXome-Hidden Markov Model 
(XHMM), a statistical package designed specifically to detect CNVs from normalized 
read-depth data from targeted sequencing (61). Members of one OCD trio and four 
control trios were filtered by the XHMM default quality control methods and 
consequently were not included in analyses. We then used an in-house pipeline following 
a protocol (61) combining PLINK, Plink/Seq, and ANNOVAR software to annotate rare 
CNVs (frequency <1% among all individuals in the sample set) in the children as 
inherited or de novo. Plink/Seq quality thresholds for de novo calls were set at SQ ≥ 70 
(high probability of a CNV in the child) and NQ ≥ 70 (high probability of no CNV in the 
parents). Following annotation, we discarded maternal and paternal CNVs not transmitted 
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to the child. We discarded one additional outlier OCD trio with an excess of CNV calls 
(>20) in the child. After obtaining a set of de novo CNV calls, we used the AnnotSV 
webtool (65) to identify de novo CNVs that were not present in the Database of Genomic 
Variants (DGV; not previously detected in the human population) (66). 
 
Burden Analysis 
Mutation Rates of PZVs 
 Within cases and controls, we calculated the rates of single-nucleotide PZVs per 
base pair. To account for differences in coverage between the two cohorts, we calculated 
the number of callable base pairs per trio using the GATK DepthOfCoverage tool (58). 
Callable bases were defined as those with a sequencing depth of at least 20 reads in all 
three family members at that genomic position. To perform the burden analysis 
(comparing mutation rates in cases vs. controls), we used the rateratio.test R package to 
calculate mutation rate ratios with a two-sided p-value (67). We used the wANNOVAR 
webtool using RefSeq hg19 gene definitions (analogous to b37d5, our reference genome) 
to classify PZVs as LGD (adding/removing a stop codon or altering a canonical splice 
site), nonsynonymous (predicted to alter a gene-encoded protein sequence), synonymous 
(within the coding sequence but not affecting the protein product), or noncoding (68, 69). 
For nonsynonymous variants, we used PolyPhen-2 to computationally predict the effects 




Rates of CNVs 
 We calculated CNV rates as the number of CNVs per individual and as the 
proportion of individuals in each cohort with at least one CNV. For both measures, we 
performed the burden analysis with the rateratio.test R package as described above using 
a two-sided p-value. Rate measurements were calculated together and separately for 
deletions and duplications, and by size bin (<10 kb, 10-30 kb, >30 kb). We did not 
perform a comparison of CNV lengths between cases and controls as the start and end 
points (breakpoints) of CNVs may fall outside the exomic intervals targeted by WES, 
rendering length measurements inaccurate. 
 
 
Exploratory Risk Gene Pathway, and Expression Analyses 
We used the wANNOVAR webtool to identify genes containing our putative 
PZVs and the AnnotSV webtool to identify genes overlapping de novo CNVs. Genes 
overlapping novel (not present in DGV) de novo CNVs were labeled as putative OCD 
risk genes and used as the input gene list for our pathway analysis. Metascape was used 
to perform pathway analyses using ontology terms pulled from KEGG Pathway, GO 
Biological Processes, Reactome Gene Sets, Canonical Pathways and CORUM 
knowledgebases (71). All known genes in the human genome were used in the 
enrichment background to calculate an enrichment factor (the ratio between the observed 
counts and the counts expected by chance) and an associated p-value. These analyses 
were inputted into Cytoscape to generate and visualize an interactive enrichment network 
of ontology terms for the gene list (72). Spatio-temporal expression analyses were 




   
RESULTS 
Mutation Rates and Burden Analysis 
PZV Rates 
The rate of all single-nucleotide PZVs per base pair was not significantly different 
between OCD probands (4.90 x 10-9) and controls (4.93 x 10-9), rate ratio = 0.994 (95% 
confidence interval = 0.613-1.56), two-sided p = 1. Of the putative PZVs identified in 
OCD probands, none are likely gene disrupting (LGD; alteration of a splice site or stop 
codon) and 28% are missense mutations predicted by PolyPhen-2 to be probably 
damaging (Mis-D). The rate of putative damaging PZVs (LGD and Mis-D) per base pair 
also is not significantly different in OCD probands (1.45 x 10-9) than in controls (1.09 x 
10-9), rate ratio = 1.33 (95% confidence interval = 0.475-3.27), two-sided p = 0.653 
(Table 1). We observe no recurrence of PZVs in the same gene in unrelated probands 
(Table 2). 
 
Variant class Variant count Mutation rate 
























































LGD 0 3 0 0.164 0 0.00553 --a -- 
Damaging 
(LGD + Mis-D) 




Unknown 0 2 0 0.109 0 0.00369 --a -- 
 
Table 1. PZVs are not enriched in OCD probands compared to unaffected controls. 
Variants were annotated with Annovar, using RefSeq hg19 gene definitions. 
“Nonsynonymous” variants include all missense and LGD variants. Mis-D are “probably 
damaging” missense variants, Mis-P are “possibly damaging” missense variants, and 
Mis-B are “benign” missense variants based on PolyPhen-2 scoring. LGD variants are 
those adding/removing a stop codon or affecting a canonical splice site. “Unknown” 
variants are included as coding variants but are not included in the synonymous or 
nonsynonymous counts. Mutation rates were calculated as the number of variants divided 
by the number of “callable” bases (see supplementary methods). Estimates of inherited 
mutations per individual were calculated by multiplying the mutation rate by the size of 
the RefSeq hg19 coding exome (33,828,798 bp). Mutation rates were compared with a 
two-sided rate ratio test. 




 The mutant allele fractions of PZVs was not significantly different between the 
OCD trios (mean = 0.236, SD = 0.126) and controls (mean = 0.213, SD = 0.107), t = 
0.922, df = 119, two-sided p = 0.358. Additionally, when considering only PZVs with a 
mutant allele fraction of at least 0.2, as in Dou et. al (49), the mutation rate for damaging 
PZVs in OCD (6.21 x 10-10) was not significantly different from that in controls (3.82 x 
10-10), RR= 1.63 (95% CI = 0.271-7.12), two-sided p = 0.696. No children in the OCD or 
control trios harbored multiple likely damaging PZVs, so we did not perform a separate 
calculation comparing the proportion of children with at least one PZV in each group. 
Table 2 shows all putative PZVs detected in the OCD trios. 
 
Position Base pair 
change 




1:10166307 G>A missense   B UBE4B 8186 
2:64113007 G>T missense   D UGP2 8167 
2:102018919 C>T synonymous    RFX8 8097 
2:118578877 G>A intronic  DDX18 8144 
2:179476243 G>A missense   D TTN 8214 
4:887739 G>C missense   D GAK 8141 
4:144620034 A>G synonymous    FREM3 8197 
5:172123965 C>G intergenic  NEURL1B; 
LOC101928093 
8065 
6:109312016 C>T missense   D SESN1 8074 
7:48065402 G>A intronic  SUN3 8206 
7:99996911 C>T intronic  PILRA 8167 
8:22012961 G>T synonymous    LGI3 8138 
10:33140834 T>G missense   P CCDC7 8211 
12:95604617 T>C missense   B FGD6 8183 
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16:69482126 A>G intronic  CYB5B 8139 
17:8381651 C>A intronic  MYH10 8040 
17:18167126 G>A missense   B MIEF2 8038 
17:26488199 G>A missense   D NLK 8149 
19:1083061 C>T missense   P ARHGAP45 8018 
19:19765409 C>T missense   D ATP13A1 8094 
20:33855171 C>T synonymous    MMP24 8140 
21:28793094 A>G intergenic  ADAMTS5; 
LINC00113 
8168 
22:51133459 C>T synonymous    SHANK3 8042 
X:110970140 C>T synonymous    ALG13 8002 
X:115303777 T>C missense   D AGTR2 8172 
 
Table 2. Putative PZVs detected in OCD samples. For PolyPhen2 missense variant 
predictions, D represents Mis-D or “probably damaging,” P represents Mis-P or “possibly 
damaging,” and B represents Mis-B or “benign.” Two PZVs are found in the same child 
from family 8167. 
 
CNV Rates 
The rate of all rare (de novo and inherited) CNVs per child is 2.42 in OCD cases 
and 1.72 in controls, rate ratio = 1.41 (95% confidence interval = 1.23-1.62), two-sided p 
= 2.65x10-6. The rate of rare de novo CNVs per child is 0.305 in OCD cases and 0.0854 
in controls, rate ratio = 3.55 (95% confidence interval = 2.22-5.54), two-sided p = 
2.97x10-7. For novel de novo CNVs not present in DGV, the rate per child is 0.192 in 
OCD cases and 0.0492 in controls, rate ratio = 3.90 (95% confidence interval = 2.13-








CNV type CNV count 



















































































































10-30 DEL 3 9 2.60 0.295 
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Total DEL 8 10 6.25 0.000840 
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(0.0808) (0.0129) (2.14-17.6) 















Table 3. Rates of rare CNVs are higher in OCD probands compared to unaffected 
controls. DEL = deletion; DUP = duplication. Significance threshold with Bonferroni 
correction for multiple testing is 0.00139. 
 
Considering deletions and duplications together, the proportion of children with at 
least one CNV is not statistically significantly different between OCD cases and controls 
for all rare and for novel de novo CNVs following multiple testing correction; however, 
significantly more OCD cases have at least one rare de novo CNV compared to controls 
(see Table 4). Looking only at deletions, the proportion of children with at least one rare 
de novo or inherited deletion is higher in OCD trios (0.606) than in controls (0.448), chi-
square = 8.86, p=0.00292. The proportion of children with at least one rare de novo 
deletion is higher in OCD trios (0.111) than in controls (0.0298), chi-square=15.5, 
p=0.000082. The proportion of children with at least one novel de novo deletion is higher 
in OCD trios (0.0707) than in controls (0.0130), chi-square=15.3, p=0.000091. In 
contrast, the proportion of children with at least one CNV is not significantly different 
between cases and controls for all rare de novo or inherited duplications (OCD=0.747, 
control=0.658, chi-square=3.14, p=0.0765), for rare de novo duplications (OCD=0.0909, 
control=0.0543, chi-square=2.13, p=0.144), and for novel de novo duplications 
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(OCD=0.0404, control=0.0349, chi-square=0.0767, p=0.782). These data are shown in 
Figure 4 and Table 4. 
 
 
Figure 4. Rare, rare de novo, and novel de novo deletion rates are increased in OCD 
cases compared to controls. Within each CNV category, rates are calculated as proportion 







CNV type Proportion of children 








All rare DEL 0.606 0.448 8.86 0.00292 
DUP 0.747 0.658 3.14 0.0765 
DEL+DUP 0.869 0.796 2.97 0.0846 
Rare de 
novo 
DEL 0.111 0.0298 15.5 0.000082 
DUP 0.0909 0.0543 2.13 0.144 
DEL+DUP 0.182 0.084 10.1 0.00148 
Novel de 
novo 
DEL 0.0707 0.0130 15.3 0.000091 
DUP 0.0404 0.0349 0.0767 0.782 
DEL+DUP 0.0909 0.0479 3.25 0.0713 
 
Table 4. Proportion of children with at least one CNV. Deletions are enriched in OCD 
cases vs. controls across all variant classes. Significance threshold with Bonferroni 
correction for multiple testing is 0.00556. 
 
 The 19 putative novel de novo CNVs detected are present in nine OCD cases, 
with one case containing eight of these CNVs and another containing four. In total, these 







2:26587170-26611971 DUP 24801 SELENOI 
2:100217897-100218083 DUP 186 AFF3 
2:112536252-112545897 DEL 9645 ANAPC1 
2:167055182-167085482 DEL 30300 SCN1A-AS1; SCN9A 
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2:170657471-170681107 DUP 23636 METTL5; SNORD3K; SSB 
2:230456296-230456604 DUP 308 DNER 
3:129546646-129547221 DUP 575 TMCC1 
3:130305350-130318654 DEL 13304 COL6A6 
5:80911292-80946158 DEL 34866 SSBP2 
6:42897309-42897459 DUP 150 CNPY3; CNPY3-GNMT 
7:26245988-26251794 DEL 5806 CBX3 
8:101718922-101730116 DEL 11194 PABPC1 
11:129780371-129780551 DUP 180 PRDM10 
12:69124890-69279669 DEL 154779 CPM; LOC100130075; MDM2; 
NUP107; SLC35E3 
15:29367124-30092905 DUP 725781 APBA2; FAM189A1; 
LOC100130111; NSMCE3; TJP1 
15:45777361-45783079 DUP 5718 SLC30A4 
17:71205668-71205907 DUP 239 FAM104A 
18:45368198-45423127 DEL 54929 SMAD2 
19:49926469-49926596 DUP 127 PTH2 
 
Table 5. Putative novel de novo CNVs detected in OCD samples. 
  
Pathway Analysis 
 For the list of 31 genes overlapping novel de novo OCD CNVs (the subclass of 
CNVs with the highest rate ratio in the burden analysis), Metascape found eight ontology 
terms that had a p-value < 0.01, had an enrichment factor > 1.5, and were associated with 
at least three genes from the input list. Pathway analysis showed the highest enrichment 
for the ontology terms cell cycle (p=0.00035), associated with SMAD2, MDM2, and 
ANAPC1 genes; protein export from the nucleus (p=0.0010), associated with MDM2, 
30 
 
SSB, and NUP107; and SUMO E3 ligases (p=0.0011), associated with MDM2, 
NSMCE3, and NUP107. Figure 5 shows all eight terms mapped in a network based on 
relatedness of terms, with terms with a similarity > 0.3 connected by edges (lines). Table 
6 shows the genes contributing to each term and the corresponding p-value. 
 
 
Figure 5. Pathway analysis of 31 genes overlapping novel de novo OCD CNVs. Nodes 
are labeled by their corresponding gene ontology description, colored according to their 




Ontology term Gene hits p-Value 
Cell cycle SMAD2; MDM2; ANAPC1 0.00035 
Protein export from nucleus MDM2; SSB; NUP107 0.0010 
SUMO E3 ligases SUMOylate target 
proteins 
MDM2; NSMCE3; NUP107 0.0011 
SUMOylation MDM2; NSMCE3; NUP107 0.0012 
Nuclear export MDM2; SSB; NUP107 0.0013 
Nucleobase-containing compound 
transport 
SSB; SLC35E3; NUP107 0.0024 
Cell cycle checkpoints MDM2; NUP107; ANAPC1 0.0042 
Nucleocytoplasmic transport MDM2; SSB; NUP107 0.0064 
 
Table 6. Significant gene ontology terms from pathway analysis the set of 31 genes 
overlapping novel de novo OCD CNVs. Genes (“hits”) contributing to each term and the 
p-value for enrichment of the term are shown. 
 
Clinical Features of Notable Cases 
 Five CNVs, each from a separate OCD patient, contribute to the eight significant 
ontology terms from the pathway analysis (Table 7). All five patients have other 
psychiatric comorbidities, notably Tourette Syndrome (TS) in all cases. The child from 
family 8134 previously was found to have a de novo, germline, predicted-damaging 
missense mutation in the CHD8 gene (44), though there is no history of ASD or 














8134 DUP METTL5; SNORD3K; SSB Male --b TS, ADHD, SAD, 
irritability 
8168 DEL ANAPC1 Male 11 TS 
8171 DEL CPM; LOC100130075; 
MDM2; NUP107; SLC35E3 
Male 5 TS, ADHD 
8205 DEL SMAD2 Male 6 TS, current ADHD 
symptoms, ASD/PDD, 
congenital anomalies 
8221 DUP APBA2; FAM189A1; 
LOC100130111; NSMCE3; 
TJP1 
Male 8 TS, ADHD, ASD/PDD 
 
Table 7. Clinical features of OCD cases with putative novel de novo CNVs contributing 
to significant ontology terms. TS = Tourette Syndrome, ADHD = attention deficit 
hyperactivity disorder, SAD = separation anxiety disorder, ASD/PDD = flagged for 
autism spectrum disorders/pervasive developmental disorders. Congenital anomalies are 
flagged in the phenotypic data but not further specified. 
aAge of OCD onset in years. 
bData not available. 
 
Expression Analysis 
 We performed an expression analysis of 31 genes overlapping novel de novo 
OCD CNVs across brain regions and developmental time periods. No expression 
networks within the CSEA brain region and development expression dataset were 
enriched for these putative OCD risk genes. Of note, the Cerebellum Early Fetal network 
contained 4 OCD risk genes (DNER, PRDM10, SCN9A, TMCC1), though it did not reach 






 We successfully applied variant calling approaches to detect PZVs and CNVs in 
WES. These variants still require experimental validation before we can use them in more 
rigorous risk gene and other downstream analyses. However, we can begin to draw 
inferences from our burden analyses about the potential role of these types of variation in 
OCD pathogenesis and from our pathway analysis about potential biological mechanisms 
significant in OCD. 
 In this study, we first aimed to characterize the contribution of PZVs to OCD. Our 
burden analysis showed that, counter to our expectations, likely damaging PZVs were not 
enriched in OCD cases compared to controls. This finding does not support our 
hypothesis that damaging PZVs contribute to OCD pathogenesis. However, we may have 
had difficulty detecting PZVs due to tissue- or cell-specificity. Somatic variants may be 
present only in a specific tissue, and even within this tissue may affect only a subset of 
cell types at certain developmental stages. A challenge to our approach is that by 
studying whole blood, we may not detect tissue-specific mosaicism (for example, mosaic 
variants present only in the brain). Furthermore, studying bulk tissue (blood) instead of 
single cells may decrease our ability to detect mosaicism due to the presence of normal 
cells in the tissue, which may overwhelm the signal from a minority of cells harboring 
damaging mutations. 
Additionally, our burden analysis may be hampered by insufficient power to 
detect differences between the cohorts. Our power to detect differences in the rate of all 
PZVs for cases and controls is estimated to be 0.828 based on rate ratios previously 
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reported in the literature (see Power Calculations in Supplementary Methods). This 
power should be sufficient (above 0.8) to detect differences, suggesting our failure to find 
a difference in the rate of all PZVs reflects a true lack of statistical significance. This 
mirrors our previous finding of no statistical difference in the rate of all germline de novo 
variants in the same samples (44). However, we had hypothesized that we would see a 
significantly higher rate of likely damaging PZVs in cases vs. controls. For this subset of 
PZVs, our power to detect differences in mutation rate between the two groups is 0.423, 
which is significantly below what we would like our power to be when using a 
significance cutoff of 0.05. As we continue collecting WES for more OCD trios and our 
sample size increases, we may have more power to detect significant differences in 
damaging PZV burden. 
 The proportion of children with putative rare deletions of all classes was greater 
for OCD patients than controls, while there was no difference in the proportion of OCD 
and control children with rare duplications. This result is consistent with previous 
microarray studies of CNVs in OCD (11, 51, 52). We might expect that deletions are 
more likely to have a deleterious effect compared to duplications by inducing a 
haploinsufficiency-like effect. However, duplications also could have a highly damaging 
effect if their endpoint falls within a gene and disrupts the protein-coding region. Like the 
PZVs, the detected putative CNVs should be validated experimentally to remove false 
positives. If the enrichment of OCD patients with deletions holds after validation, this 
finding would provide further evidence that rare deletions play a role in OCD 
pathogenesis. Additionally, as we continue to sequence more OCD trios, we may detect 
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additional risk genes and new biological pathways or expression networks enriched for 
these genes. 
Genes overlapping novel de novo CNVs in OCD patients are associated with 
ontology terms related to cell cycle and nuclear transport. The associate with cell cycle 
terms is consistent with findings that many genes related to neurodevelopmental 
disorders play a role in neural stem cell proliferation and differentiation and that 
particular genes are associated both with neurodevelopmental disorders and with cancers 
(74). Similarly, many genes related to nuclear transport or nuclear localization, namely 
those encoding transcription factors and chromatin modifiers, have been associated with 
neurodevelopmental disorders (75-79). These findings are consistent with our previous 
study of germline SNVs and indels in OCD WES. In the previous study we identified 
CHD8, which encodes a DNA helicase that regulates gene expression through chromatin 
remodeling, as a high-confidence OCD risk gene. 
Like many patients with OCD, most of the OCD cases with CNVs contributing to 
the significant ontology terms had multiple comorbid psychiatric disorders. All cases had 
TS and four of the five had ADHD diagnoses or symptoms present at the time of 
evaluation. Notably, two cases were flagged for a diagnosis of autism, one of which also 
was flagged for congenital anomalies (unspecified in our available clinical data). These 
cases highlight the challenges in teasing apart the contribution of genetic variants to OCD 
and to comorbid features. Given recent evidence that OCD and TS have overlapping 
genetic etiologies, future risk gene analyses in OCD should examine the overlap with 
genes implicated in TS (44, 80). Future efforts to collect patients with OCD and without 
comorbid disorders may help isolate potential OCD-specific genetic etiologies. Further, 
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deep phenotyping of enrolled patients would allow us to interrogate genetic factors that 
could contribute to the clinical heterogeneity of OCD. By attempting to sort patients 




We intend to validate our detected likely damaging PZVs and de novo CNVs in 
OCD cases with digital droplet PCR (ddPCR), a technique capable of validating very 
low-frequency mosaic variants (81). In ddPCR, the DNA sample is diluted into droplets, 
each containing one molecule of the target allele. A PCR reaction with fluorescent tags 
marking the target region is run in each droplet, and quantification of the tag signal 
allows calculation of allele frequency. Based on these validation results, we will optimize 
the pipeline parameters to obtain high-confidence sets of variants. Following validations, 
we will compare our set of detected CNVs in the WES data generated from our control 
samples to microarray data previously generated in the same samples (57). Additionally, 
we will compare the rates of CNVs detected in our WES for OCD patients to rates of 
CNVs found in previous OCD studies that used microarray data. These comparisons will 
test our hypothesis that detecting CNVs from WES data with our pipeline allows us to 
detect more CNVs, particularly smaller ones, than can be detected using microarray data. 
If our finding of CNV enrichment in OCD cases holds after validation, we will 
use information about these variants to assess the level of significance of putative OCD 
risk genes using the Transmission And De novo Association (TADA) statistical method. 
TADA uses information about inherited and de novo variants to predict a gene’s 
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likelihood of association with a disease and strongly implicates a gene in disease if 
damaging de novo mutations are seen in the same gene in more than one unrelated 
proband (82). This statistical method has been used to identify 99 high-confidence risk 
genes in autism (83, 84), and we have used it to identify risk genes based on germline de 
novo variants in OCD (44) and Tourette syndrome (56). By incorporating CNVs into this 
model, we are likely to identify more OCD risk genes that will rise to the level of 
statistical significance. 
Long term, this research will help lay the groundwork for further research into the 
molecular basis of OCD. Specific genes and biologic pathways implicated by our 
analyses will provide jumping-off points to guide later studies examining molecular 
mechanisms (e.g. animal and cell culture models). Ultimately, these mechanistic studies 
will point to potential drug targets and will allow for development and testing of crucial 






Sequence reads obtained from WES were aligned to the b37d5 human reference 
genome using the Burrows-Wheeler Aligner tool, PCR duplicates were marked using 
Picard's MarkDuplicates tool, and tab-delimited text file (BAM file) containing the 
aligned exome data was generated (85). The BAM file for each individual’s exome was 
used as the input for MosaicHunter and for XHMM. 
 
Power Calculations 
 To estimate our power to detect differences in mutation frequency between our 
OCD and control samples (86), we defined the following variables: 
 
Group Control children Children with OCD 
Mean callable base pairs 𝑡1 𝑡2 
Sample size 𝑁1 𝑁2 
Number of PZVs 𝑋1 𝑋2 
Rate of PZVs per individual 𝜆1 𝜆2 
 
The rate ratio of PZVs is 𝑅𝑅 =
𝜆2
𝜆1
. 𝑅𝑅0 = 1, representing the null hypothesis that the 
mutation rates of the two groups are not statistically different. 𝑅𝑅𝑎 > 1, representing the 
alternative hypothesis that the mutation rate in children with OCD is significantly greater 




Assuming nonequal mutation rates for group 1 (control children) and group 2 (children 
with OCD) with unconstrained maximum likelihood estimates, we can calculate the test 
statistic for testing the ratio of two Poisson rates as 
𝑊1 =



















=  3.818 
To calculate power, we use 





















Our significance threshold is α = 0.05, so our critical value 𝑧1−𝛼 = 1.645 using the 




We estimated 𝑅𝑅𝑎 using the rate ratio for all mosaic variants found by Freed and Pevsner 
in children with ASD compared to their unaffected siblings, which was 1.73 (46). This 







) (2.506 ∗ 107)(777)(4.93 ∗  10−9) = 18.35 
𝜎1 = √(
3.818 ∗ 1.73 + 12
3.8182
) (2.506 ∗ 107)(777)(4.93 ∗  10−9) = 7.077 
𝜙 (
1.645 ∗ 7.077 − 18.35
7.077
) = 𝜙(−0.9479) 
 
We calculate 𝜙(−0.9479) by integrating from -∞ to -0.9479 over a normal distribution 
with mean = 0 and standard deviation = 1, giving 
𝜙(−0.9479) = ∫ 𝑁𝑜𝑟𝑚𝑎𝑙(0,1)
−0.9479
−∞
= 0.172  
This gives us 
𝑃𝑜𝑤𝑒𝑟(𝑊1) = 1 − 0.172 =  0.828 
for detecting differences in the rate of all PZVs. Repeating these calculations for our 
ability to detect differences in rates of likely damaging PZVs using the rate ratio from 




The number of “callable” bases within each trio was calculated as previously 
described (44) and used to calculate PZV rates to minimize bias in calling variants 
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between case and control cohorts. Using the GATK DepthOfCoverage tool, we 
calculated the number of bases covered at ≥ 20x in all family members, with base quality 
≥20, and map quality ≥ 30 (the same thresholds required for GATK and de novo variant 
calling). For each cohort, we summed the callable base pairs in every family. The sum of 
coding and noncoding callable bases was used as the denominator for calculating rates of 
all PZVs (5100562503 bases for 183 OCD trios and 19474297328 bases for 777 control 
trios). The sum of only coding callable bases was used as the denominator for all other 
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